XML 42 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
Research And Collaboration Agreements (Sanofi To GlaxoSmithKline) (Details) (USD $)
12 Months Ended 0 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Jul. 20, 2009
Jan. 31, 2012
Aug. 31, 2012
Dec. 31, 2010
Jun. 30, 2007
Mar. 31, 2006
Oct. 31, 2002
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
License and contract revenues $ 0exel_LicenseContractandCollaborationReimbursementRevenue $ 16,321,000exel_LicenseContractandCollaborationReimbursementRevenue $ 47,450,000exel_LicenseContractandCollaborationReimbursementRevenue              
Purchase an aggregate shares of common stock 195,895,769us-gaap_CommonStockSharesIssued 184,533,651us-gaap_CommonStockSharesIssued                
Sanofi [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront and milestone payments       140,000,000.0exel_UpfrontAndMilestonePayments
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
           
Upfront payment received for license       120,000,000.0exel_CollaborationAgreementUpfrontPaymentReceivedForLicense
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
           
Upfront payment received for collaboration       20,000,000.0exel_CollaborationAgreementUpfrontPaymentReceivedForCollaboration
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
           
Withholding taxes on upfront payments       7,000,000exel_CollaborationAgreementWithholdingTaxesOnUpfrontPayments
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
           
Upfront payments, net of tax       133,000,000exel_CollaborationAgreementUpfrontPaymentsNetOfTax
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
           
Maximum amount eligible for development and regulatory milestones 745,000,000.0exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
                 
Proceeds from termination of agreement         15,300,000exel_ProceedsFromTerminationOfAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
         
License and contract revenues 0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_SanofiAventisMember
             
Merck [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Maximum amount eligible for development and regulatory milestones 239,000,000exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
                 
License and contract revenues 0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
10,700,000exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
             
Upfront cash payment         12,000,000exel_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
         
Maximum amount eligible for royalties on sales under collaborations agreement 375,000,000exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_MerckMember
                 
Daiichi Sankyo [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Maximum amount eligible for development and regulatory milestones 145,000,000exel_MaximumAmountEligibleForDevelopmentAndRegulatoryMilestonesUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
                 
License and contract revenues 0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
5,500,000exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
             
Upfront cash payment                 20,000,000exel_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
 
Research and development fund               1,500,000.0exel_ResearchAndDevelopmentFund
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
3,800,000exel_ResearchAndDevelopmentFund
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
 
Original research term, years                 15 months  
Extended research term, years               6 months    
Milestone payment           5,500,000.0exel_MilestonePayments
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
5,000,000.0exel_MilestonePayments
/ us-gaap_TypeOfArrangementAxis
= exel_DaiichiSankyoMember
     
GlaxoSmithKline [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront and milestone payments                   65,000,000.0exel_UpfrontAndMilestonePayments
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
License and contract revenues 0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
0exel_LicenseContractandCollaborationReimbursementRevenue
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
             
Research and development funding and loans                   85,000,000.0exel_ResearchAndDevelopmentFundingAndLoan
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
Purchase an aggregate shares of common stock                   3,000,000us-gaap_CommonStockSharesIssued
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
Royalty expense $ 700,000us-gaap_RoyaltyExpense
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
$ 400,000us-gaap_RoyaltyExpense
/ us-gaap_TypeOfArrangementAxis
= exel_GlaxoSmithKlineMember
               
GlaxoSmithKline [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percent of royalty on net sales 3.00%exel_PercentOfRoyaltyOnNetSale
/ us-gaap_MajorCustomersAxis
= exel_GlaxoSmithKlineMember